Testosterone replacement-induced hyperprolactinaemia: Case report and review of the literature

Annals of Clinical Biochemistry

Volumn 42, Issue 2, 2005, Pages 153-159

  Sodi, Ravinder ^a   Fikri, R ^a   Diver, M ^a   Ranganath, L ^a   Vora, J ^a  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; PROLACTIN; TESTOSTERONE;

ADENOHYPOPHYSIS; ADENOMA; ADULT; ANDROGEN THERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; IMPOTENCE; LIBIDO DISORDER; MALE; PRIORITY JOURNAL; PROLACTIN RELEASE; PROLACTINOMA; REVIEW; TRANSSPHENOIDAL HYPOPHYSECTOMY; TUMOR RECURRENCE;

ADENOMA; ADOLESCENT; AROMATASE INHIBITORS; DOPAMINE AGONISTS; ESTRADIOL; HUMANS; HYPERPROLACTINEMIA; HYPOGONADISM; HYPOPHYSECTOMY; MALE; OBESITY; PITUITARY NEOPLASMS; TESTOSTERONE;

EID: 17144418516     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563053492784     Document Type: Review

References (14)

1. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CB, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 2000; 85: 3053-7
2. Nicoletti I, Filipponi P, Fedeli L, Ambrosi F, Gregorini G, Santeusanio F. Testosterone-induced hyperprolactinaemia in a patient with a disturbance of hypothalamo-pituitary regulation. Acta Endocrinol 1984; 105: 167-72
3. Prior JC, Cox TA, Fairholm D, Kostashuk E, Nugent R. Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J Clin Endocrinol Metab 1987; 64: 391-4
4. Gillam MP, Middler S, Freed DJ, Molitch ME. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 2002; 87: 4447-51
5. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482-92
6. Yen SSC, Ehara Y, Siler TM. Augmentation of prolactin secretion by estrogen in hypogonadal women. J Clin Invest 1974; 53: 652-5
7. Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993; 59: 671-3
8. Scherrer H, Turpin G, Darbois Y, Metzger J, de Gennes JL. Pregnancy and hyperprolactinemia. Review of therapeutic measures apropos of a series of 35 patients. Ann Med Intern (Paris) 1986; 137: 621-6
9. Gooren LJ, Assies J, Asscheman H, de Siegte R, van Kessel H. Estrogen-induced prolactinoma in a man. J Clin Endocrinol Metab 1988; 66: 444-6
10. Finkelstein JS, O'Dea LS, Whitcomb RW, Crowley Jr WF. Sex steroid control of gonadotrophin secretion in the human male II. Effects of estradiol administration in normal and gonadotrophin-releasing hormone-deficient men. J Clin Endocrinol Metab 1991; 73: 621-8
11. Munemura M, Agui T, Sibley DR. Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland. Endocrinology 1989; 124: 346-55
12. Gooren LJ, van der Veen EA, van Kessel H, Harmsen-Louman W, Wiegel AR. Prolactin secretion in the human male is increased by endogenous oestrogens and decreased by exogenous/endogenous androgens. Int J Androl 1984; 7: 53-60
13. Colao A, di Sarno A, Cappabianca P, di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003; 349: 2023-33
14. Shozu M, Sebastian S, Takayama K, Hsu WT, Schultz RA, Neely K, Bryant M, Bulun SE. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med 2003; 348: 1855-65